Strides Pharma ScienceNSE:STAR -2.62%67 Net Margin % is 9.59% as of Mar. 2026, which is 3% below its 10-year median of 9.86. GuruFocus rates NSE:STAR with a GF Score™ of 67/100 and a GF Value™ of ₹773.22 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 956 Drug Manufacturers companies, Strides Pharma Science ranks better than 68.51% on this metric.
The historical rank and industry rank for Strides Pharma Science's Net Margin % or its related term are showing as below:
NSE:STAR'
s Net Margin % Range Over the Past 10 Years
Min: -15.23 Med: 9.86 Max: 78.71
Current: 11.45
NSE:STAR's Net Margin % is ranked better than 68.51% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs NSE:STAR: 11.45
Strides Pharma Science (NSE:STAR) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Strides Pharma Science Net Margin % Related Terms
Strides Pharma Science Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strides Pharma Science Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's Net Margin % distribution charts can be found below:
* The bar in red indicates where Strides Pharma Science's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strides Pharma Science (NSE:STAR) has a Net Margin % of 9.59% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Strides Pharma Science and its competitors. This is near median its historical median of 9.86. According to the industry distribution chart, Strides Pharma Science ranks #301 out of 956 companies in the Drug Manufacturers industry, placing it in the top 31.5%.
Is Strides Pharma Science's Net Margin % too high?
Strides Pharma Science's current Net Margin % of 9.59% is near median its 10-year median of 9.86. The Drug Manufacturers industry median Net Margin % is 5.56. Strides Pharma Science's value of 9.59% is 72.5% above this industry median. Based on the distribution chart, Strides Pharma Science ranks #301 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Strides Pharma Science has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Strides Pharma Science ranks #301 out of 956 companies for Net Margin %. This puts Strides Pharma Science in the upper half of its industry. The industry median Net Margin % is 5.56. Strides Pharma Science's value of 9.59% is 72.5% above this benchmark. While the company's 10-year median is 9.86 vs. the industry median of 5.56, Strides Pharma Science has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Strides Pharma Science's current Net Margin % of 9.59% is 72.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Strides Pharma Science and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strides Pharma Science's current Net Margin % is 9.59%, which is near median its own 10-year median of 9.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹773.22, compared to a current price of ₹1,082.20 — trading 40% above its estimated fair value. The current Net Margin % is 9.59%, which is near median its 10-year median of 9.86 and 72.5% above the Drug Manufacturers industry median of 5.56. Strides Pharma Science's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current Net Margin % is 9.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?
Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued.
The current stock price of ₹1,082.20 is trading 40% above its estimated GF Value™ of ₹773.22.
GuruFocus considers Strides Pharma Science to be Significantly Overvalued.
Key valuation signals for NSE:STAR:
Net Margin %: 9.59% (near median its 10-year median of 9.86)
GF Value™: ₹773.22 vs. price of ₹1,082.20 (40% above fair value)
Industry Position: 72.5% above the Drug Manufacturers median (#301 of 956)
No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
67GF Score
Get the complete analysis for NSE:STAR
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:STAR has been successfully added to your 
